脂肪原/Staurosporine/AG-CN2-0022-M005/5 mg
商品编号：
AG-CN2-0022-M005
品牌：
Adipogen Inc
市场价：
¥4400.00
美元价：
2640.00
产品分类：
其他试剂
公司分类：
Other_reagents
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
| Product Details | |
|---|---|
| Synonyms | Antibiotic AM2282; Antibiotic 230; CCRIS 3272 |
| Product Type | Chemical |
| Properties | |
| Formula | C28H26N4O3 |
| MW | 466.5 |
| Merck Index | 14:8802 |
| CAS | 62996-74-1 |
| RTECS | KC655000 |
| Source/Host Chemicals | Isolated from Streptomyces spiralis. |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | Off-white to yellow solid. |
| Solubility | Soluble in DMSO, ethyl acetate or dimethyl formamide. Insoluble in water. |
| InChi Key | HKSZLNNOFSGOKW-FYTWVXJKSA-N |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice |
Keep cool and dry. Protect from moisture. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
- Antibiotic.
- Antifungal and anti-yeast activity [1].
- Inhibits platelet aggregation induced by collagen or ADP. Has no effect on thrombin-induced platelet aggregation [2].
- Potent, cell permeable, reversible, ATP-competitive and broad spectrum inhibitor of protein kinases. Inhibits protein kinase A, CaM kinase, myosin light chain kinase, protein kinase C, protein kinase G, CDK1/cyclin B, CDK2/cyclin A, CDK4/cyclin D, CDK5/p25, GSK-3β and Pim-1 kinase [3, 4, 5, 6, 12].
- DYRK1A inhibitor (IC50=20nM) [13].
- Key apoptosis inducer [7, 8, 10, 11].
- Topoisomerase II (Topo II) inhibitor [9].
Product References
- A new alkaloid AM-2282 of Streptomyces origin. Taxonomy, fermentation, isolation and preliminary characterization: S. Omura, et al.; J. Antibiot. (Tokyo) 30, 275 (1977)
- Staurosporine, a potent platelet aggregation inhibitor from a Streptomyces species: S. Oka, et al.; Agric. Biol. Chem. 50, 2723 (1986)
- Staurosporine, a potent inhibitor of phospholipid/Ca++dependent protein kinase: T. Tamaoki, et al.; BBRC 135, 397 (1986)
- Staurosporine inhibits tyrosine-specific protein kinase activity of Rous sarcoma virus transforming protein p60: N. Nakano, et al.; J. Antibiot. (Tokyo) 40, 706 (1987)
- Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases: U.T. Ruegg & G.M. Burgess; TIPS 10, 218 (1989) (Review)
- Staurosporine: an effective inhibitor for Ca2+/calmodulin-dependent protein kinase II: N. Yanagihara, et al.; J. Neurochem. 56, 294 (1991)
- Induction of a common pathway of apoptosis by staurosporine: R. Bertrand, et al.; Exp. Cell Res. 211, 314 (1994)
- Staurosporine induces programmed cell death in embryonic neurons and activation of the ceramide pathway: D.A. Wiesner & G. Dawson; J. Neurochem. 66, 1418 (1996)
- Mechanism of topoisomerase II inhibition by staurosporine and other protein kinase inhibitors: P. Lassota et al.; J. Biol. Chem. 271, 26418 (1996)
- Characterization of the cell death process induced by staurosporine in human neuroblastoma cell lines: J. Boix, et al.; Neuropharmacology 36, 811 (1997)
- Molecular mechanism of staurosporine-induced apoptosis in osteoblasts: H.J. Chae, et al.; Pharmacol. Res. 42, 373 (2000)
- Pim-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002: M.D. Jacobs, et al.; J. Biol. Chem. 280, 13728 (2005)
- Generation of potent and selective kinase inhibitors by combinatorial biosynthesis of glycosylated indolocarbazoles: C. Sanchez, et al.; Chem. Commun. 2009, 4118 (2009)
品牌介绍
Adipogen公司由三个子公司组成，分别是Adipogen,Inc.(韩国),AdipogenSA(瑞士)和 AdipogenCorporation(美国圣地亚哥)。总部设在美国，运营总部在瑞士利斯塔尔。Adipogen公司专门从事生命科学研究试剂的开发，如癌症、免疫、炎症、代谢疾病（糖尿病、肥胖）、干细胞和神经退行性疾病等领域。其重点关注开发创新优质的ELISA试剂盒。另外，也可提供抗体和蛋白产品，Adipogen拥有自己的化学实验室，致力于开发创新型小分子化合物。
联络我们
